Delivery Order SPE2DB20D7059-SPE2DB24FQAV9

Award Date 3/11/24
Potential Completion Date 3/12/24
Potential Value $1.6K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,557,859 units of Advair HFA 230-21 MCG Inhaler 12GM. The contract has a completion date of February 6, 2024 and a potential value of $8,550.95. This delivery order is part of a larger, single-award indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, valued up to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,862.36 to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The contract is for the delivery of Advair HFA 230-21 MCG inhalers to support military treatment programs and facilities. The delivery order was issued under an existing indefinite delivery contract (IDC) between DLA and AmerisourceBergen Drug Corp, which has a...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract worth $3,549.84 to Amerisourcebergen Drug Corp, a leading pharmaceutical distribution company, for the provision of Advair HFA 230-21 MCG Inhaler 12GM. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to supply a comprehensive range of pharmaceutical products and medical supplies to military...
The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Advair HFA 230-21 mcg inhalers. The $3,936.48 order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00, to deliver a comprehensive range of pharmaceutical products and medical supplies in...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract worth $1,041.32 to provide 4,564,171,744 units of the pharmaceutical product Advair HFA 115-21 MCG Inhaler 12GM. The contract has an ultimate completion date of April 5, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of...
The Defense Logistics Agency (DLA) awarded a $4,866.80 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,248,106 units of the Advair HFA 115-21 MCG inhaler (12 gram). This delivery order is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA Troop Support Medical, valued at up to $999,999,999.00 and effective through December 31, 2025. The IDC serves as the...
The U.S. Defense Logistics Agency (DLA) awarded a $10,444.65 firm-fixed-price delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,566,405,273 units of Advair HFA 230-21 MCG Inhaler (12 gm). This order is a part of AmerisourceBergen's existing $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $7,982.52 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a for-profit organization. The delivery order is for the supply of Advair HFA 230-21 mcg inhaler, 12 gm. This award is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, with a potential value of up to $999,999,999.00, to provide a comprehensive range of pharmaceuticals and...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Advair HFA 45-21 mcg inhalers. The $2,706.60 contract has an ultimate completion date of April 1, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,261,619 units of the pharmaceutical product Advair HFA 115-21 MCG Inhaler 12GM. The contract has a ceiling value of $19,030.95 and a period of performance through April 15, 2024. This delivery order contract is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp,...
  • SPE2DB20D7059
    Indefinite Delivery Contract
  • SPE2DB20D7059-SPE2DB24FQAV9
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,562.04 to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation, to provide Advair HFA 115-21 MCG inhalers. This award is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that was previously awarded to Amerisourcebergen Drug Corp by DLA for the provision of a comprehensive range of pharmaceutical products and medical supplies to military treatment programs and facilities worldwide. The contract has a performance period through December 31, 2025 and does not include any set-aside designations.

Generated 6/10/24, 9:38 AM